Payment overview · 2025
General Payments
$767.45
42 reported records · 17 companies
Healthcare provider profile · identity verified
Christopher James Hanson, M.D., M.B.A
Allopathic & Osteopathic Physicians|Family Medicine · CARBONDALE, IL · NPI 1447514971
Verified facts
What the public records show
CMS Open Payments records show Christopher James Hanson, M.D., M.B.A received $767.45 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Ozempic, Rexulti, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.46 | 21.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.31 | 15.9% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.82 | 11.6% | 5 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $56.43 | 7.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.90 | 6.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.06 | 5.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.99 | 4.8% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.96 | 4.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.04 | 4.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.72 | 3.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.68 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.12 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.98 | 2.5% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $17.89 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.54 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.52 | 1.8% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.03 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $767.45 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $122.31 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.31 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.62 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.93 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $56.43 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.90 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.90 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.22 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.99 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.89 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $10.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 81 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
81 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1471 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1273 | 183 |
| Gabapentin | Gabapentin | 1004 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 942 | 144 |
| Furosemide | Furosemide | 852 | 110 |
| Eliquis | Apixaban | 717 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 704 | 96 |
| Lisinopril | Lisinopril | 701 | 127 |
| Tamsulosin Hcl | Tamsulosin Hcl | 660 | 111 |
| Potassium Chloride | Potassium Chloride | 597 | 62 |
| Famotidine | Famotidine | 589 | 70 |
| Trazodone Hcl | Trazodone Hcl | 558 | 62 |
| Metformin Hcl | Metformin Hcl | 537 | 79 |
| Donepezil Hcl | Donepezil Hcl | 534 | 39 |
| Omeprazole | Omeprazole | 526 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 525 | 84 |
| Quetiapine Fumarate | Quetiapine Fumarate | 523 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 513 | 116 |
| Fluoxetine Hcl | Fluoxetine Hcl | 462 | 37 |
| Mirtazapine | Mirtazapine | 454 | 42 |
| Sertraline Hcl | Sertraline Hcl | 440 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 431 | 78 |
| Hydrochlorothiazide | Hydrochlorothiazide | 427 | 94 |
| Losartan Potassium | Losartan Potassium | 426 | 99 |
| Metoprolol Tartrate | Metoprolol Tartrate | 404 | 71 |
| Carvedilol | Carvedilol | 375 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 343 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 343 | 39 |
| Montelukast Sodium | Montelukast Sodium | 336 | 76 |
| Lorazepam | Lorazepam | 328 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 326 | 39 |
| Meloxicam | Meloxicam | 320 | 58 |
| Pregabalin | Pregabalin | 319 | 53 |
| Buspirone Hcl | Buspirone Hcl | 306 | 26 |
| Simvastatin | Simvastatin | 290 | 50 |
| Memantine Hcl | Memantine Hcl | 287 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 284 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 266 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 265 | 48 |
| Tramadol Hcl | Tramadol Hcl | 253 | 53 |
| Divalproex Sodium | Divalproex Sodium | 252 | 32 |
| Sucralfate | Sucralfate | 227 | 31 |
| Aripiprazole | Aripiprazole | 219 | 18 |
| Levetiracetam | Levetiracetam | 212 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 61 |
| Prednisone | Prednisone | 191 | 119 |
| Risperidone | Risperidone | 191 | 15 |
| Olanzapine | Olanzapine | 187 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 23 |
| Haloperidol | Haloperidol | 179 | 12 |
| Allopurinol | Allopurinol | 172 | 33 |
| Clonazepam | Clonazepam | 170 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 168 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 165 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 162 | 123 |
| Spironolactone | Spironolactone | 157 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 149 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 143 | 20 |
| Diazepam | Diazepam | 140 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 137 | 65 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 137 | 32 |
| Bupropion Xl | Bupropion Hcl | 136 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 136 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 25 |
| Baclofen | Baclofen | 126 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 126 | suppressed |
| Alprazolam | Alprazolam | 122 | 20 |
| Januvia | Sitagliptin Phosphate | 122 | 18 |
| Lamotrigine | Lamotrigine | 122 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 45 |
| Ozempic | Semaglutide | 115 | 25 |
| Warfarin Sodium | Warfarin Sodium | 109 | 14 |
| Jardiance | Empagliflozin | 107 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 107 | 27 |
| Atenolol | Atenolol | 106 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 106 | 18 |
| Topiramate | Topiramate | 104 | 22 |
| Trulicity | Dulaglutide | 103 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 97 | 27 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 94 | 12 |
| Nifedipine Er | Nifedipine | 94 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 90 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 14 |
| Propranolol Hcl | Propranolol Hcl | 86 | 15 |
| Ezetimibe | Ezetimibe | 85 | 17 |
| Rybelsus | Semaglutide | 81 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 78 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 36 |
| Gemfibrozil | Gemfibrozil | 74 | 14 |
| Xarelto | Rivaroxaban | 74 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | suppressed |
| Linzess | Linaclotide | 71 | 20 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 67 | 39 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Myrbetriq | Mirabegron | 65 | suppressed |
| Tradjenta | Linagliptin | 65 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 64 | 20 |
| Lovastatin | Lovastatin | 64 | suppressed |
| Lacosamide | Lacosamide | 63 | suppressed |
| Lidocaine | Lidocaine | 63 | 20 |
| Celecoxib | Celecoxib | 62 | suppressed |
| Finasteride | Finasteride | 61 | 16 |
| Paliperidone Er | Paliperidone | 61 | suppressed |
| Nystatin | Nystatin | 59 | 45 |
| Loperamide | Loperamide Hcl | 58 | 17 |
| Midodrine Hcl | Midodrine Hcl | 58 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 56 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 55 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 54 | suppressed |
| Ibuprofen | Ibuprofen | 54 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 13 |
| Amantadine | Amantadine Hcl | 53 | suppressed |
| Oxycontin | Oxycodone Hcl | 53 | suppressed |
| Naproxen | Naproxen | 51 | suppressed |
| Glipizide | Glipizide | 50 | 14 |
| Primidone | Primidone | 50 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 49 | suppressed |
| Lactulose | Lactulose | 48 | 11 |
| Lithium Carbonate | Lithium Carbonate | 48 | suppressed |
| Ranolazine Er | Ranolazine | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Alprazolam Er | Alprazolam | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 13 |
| Dutasteride | Dutasteride | 43 | 14 |
| Irbesartan | Irbesartan | 43 | 11 |
| Prazosin Hcl | Prazosin Hcl | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Austedo | Deutetrabenazine | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 19 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 38 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Fentanyl | Fentanyl | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Glyburide | Glyburide | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 26 |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 14 |
| Doxepin Hcl | Doxepin Hcl | 31 | suppressed |
| Pentoxifylline | Pentoxifylline | 31 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Nystop | Nystatin | 29 | 21 |
| Azithromycin | Azithromycin | 28 | 24 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Cimetidine | Cimetidine | 26 | suppressed |
| Clozapine | Clozapine | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 19 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 17 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 20 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 16 |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 20 | 18 |
| Belsomra | Suvorexant | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Dofetilide | Dofetilide | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Risperidone Er | Risperidone Microspheres | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Tolvaptan | Tolvaptan | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Alprazolam Xr | Alprazolam | 12 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $767.45 · 42 records | Novo Nordisk Inc | Auvelity, FARXIGA, Fibroscan, GEMTESA, GVOKE HYPOPEN, Kerendia, Korlym, LEQVIO, MOUNJARO, Motpoly XR, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error